Viomellein

Viomellein is a SUMOylation inhibitor with antibacterial and anticancer activities. Viomellein inhibits biofilm formation of strains produced from the fungus Aspergillus ochraceus from the Mediterranean sponge Agelas oroides. Viomellein exhibits cytotoxicity against A2780 human ovarian cancer cells with an IC50 value of 5.0 μM. Viomellein also inhibits SUMOylation of RanGAP1 (GTPase activating protein) with an IC50 of 10.2 μM[1][2][3].

Product Specifications

CAS Number

[55625-78-0]

UNSPSC

12352005

Target

Bacterial; E1/E2/E3 Enzyme

Type

Natural Products

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/viomellein.html

Smiles

O=C1C2=C(O)C3=C(C(C(OC)=C(C4=C(OC)C=C5C=C(C[C@@H](C)O6)C(C6=O)=C(O)C5=C4O)C3=O)=O)C=C2C[C@@H](C)O1

Molecular Formula

C30H24O11

Molecular Weight

560.50

References & Citations

[1]Cryptic Secondary Metabolites from the Sponge-Associated Fungus Aspergillus ochraceus|[2]Kumla D, et al. 1,3-Dioxepine and spiropyran derivatives of viomellein and other dimeric naphthopyranones from cultures of Aspergillus elegans KUFA0015 and their antibacterial activity. Phytochemistry. 2021 Jan;181:112575|[3]Hirohama M, et al. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2. ACS Chem Biol. 2013 Dec 20;8 (12) :2635-42.